EuBiologics Co., Ltd. (206650.KQ)
- Previous Close
13,440.00 - Open
13,500.00 - Bid --
- Ask --
- Day's Range
13,070.00 - 13,970.00 - 52 Week Range
6,260.00 - 14,500.00 - Volume
676,502 - Avg. Volume
537,417 - Market Cap (intraday)
349.74B - Beta (5Y Monthly) 1.27
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
14,000.00
EuBiologics Co., Ltd., a biopharmaceutical company, provides vaccines for epidemics in South Korea. It offers Euvichol Plus, an oral cholera prevention vaccine; and rCRM197, a diphtheria toxoid vaccine. The company also provides EcML, a vaccine for cell membrane, as well as offers COVID-19 diagnostic kits. In addition, it offers CMO services comprising of drug product production, cell bank production, and drug substance production. Further, the company provides CRMO services, including cell line development, GMP production, validation, and the regulatory support; and operates facilities that manufacture protein-based therapeutics and antibodies. Additionally, it offers contract testing services that include lot release, stability, raw material, and method validation testing services. EuBiologics Co., Ltd. was founded in 2010 and is headquartered in Seoul, South Korea.
www.eubiologics.com--
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Related News
Performance Overview: 206650.KQ
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 206650.KQ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 206650.KQ
Valuation Measures
Market Cap
489.95B
Enterprise Value
493.24B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.06
Price/Book (mrq)
4.40
Enterprise Value/Revenue
7.11
Enterprise Value/EBITDA
-112.31
Financial Highlights
Profitability and Income Statement
Profit Margin
-20.01%
Return on Assets (ttm)
3.07%
Return on Equity (ttm)
-13.70%
Revenue (ttm)
69.37B
Net Income Avi to Common (ttm)
-13.88B
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
11.49B
Total Debt/Equity (mrq)
14.10%
Levered Free Cash Flow (ttm)
-30.18B
Research Analysis: 206650.KQ
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 206650.KQ
206650.KQ does not have Company Insights